CureVac NV (CVAC)
2.935
-0.06
(-1.84%)
USD |
NASDAQ |
May 10, 15:36
CureVac Profit Margin (Quarterly): -384.0% for Dec. 31, 2023
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -384.0% |
| September 30, 2023 | -295.3% |
| June 30, 2023 | -889.5% |
| March 31, 2023 | -805.4% |
| December 31, 2022 | -1.10K% |
| September 30, 2022 | -424.3% |
| June 30, 2022 | -285.8% |
| March 31, 2022 | -61.93% |
| December 31, 2021 | -4.70% |
| September 30, 2021 | -490.9% |
| Date | Value |
|---|---|
| June 30, 2021 | -679.0% |
| March 31, 2021 | -1.13K% |
| December 31, 2020 | -962.5% |
| September 30, 2020 | -713.6% |
| June 30, 2020 | -29.79% |
| March 31, 2020 | -764.7% |
| December 31, 2019 | -528.0% |
| September 30, 2019 | -1.68K% |
| March 31, 2019 | -675.2% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-1.68K%
Minimum
Sep 2019
-4.70%
Maximum
Dec 2021
-623.9%
Average
-603.5%
Median
Profit Margin (Quarterly) Benchmarks
| Affimed NV | -4.89K% |
| InflaRx NV | -696.8K% |
| MorphoSys AG | 81.70% |
| BioNTech SE | -168.0% |
| Immatics NV | -164.2% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -43.12% |
| Return on Assets | -29.79% |
| Return on Invested Capital | -43.12% |
| Gross Profit Margin (Quarterly) | -137.5% |
| Operating Margin (Quarterly) | -394.9% |
| Return on Net Operating Assets | -76.14% |